Simulations Plus (SLP)
Builds drug-development simulation software and consulting services for biopharma clients.
Something off on this page? Send us feedback.
Sells model-informed drug development software and specialist consulting through Software and Services segments. Revenue is concentrated in the Americas, with EMEA and Asia Pacific customers, and the business depends on biopharma R&D spending, regulated drug-development workflows, and competition from scientific software providers, CROs, in-house teams, academia, and open-source tools.
Builds model-informed drug development tools used across discovery, clinical research, trial operations, regulatory work, and commercialization. Software centers on GastroPlus, ADMET Predictor, and MonolixSuite, while Services covers PKPD, PBPK, QSP/QST, and regulatory strategy consulting.
Commercial activity is concentrated in the Americas, with additional EMEA and Asia Pacific customers. The company is headquartered in Research Triangle Park, operates with a remote-work model, and has added clinical-training and QSP capabilities through acquisitions.
Execution depends on scientific credibility, product renewal, expert consulting capacity, and biopharma client spending. Competition includes specialist software vendors, CROs, in-house client teams, academic and government groups, open-source alternatives, and fast-moving AI/ML tools.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 18, 2026 | Craig-Hallum | Target | Target: $56 | Target: $18.50 |
| Jun 17, 2026 | William Blair | Downgrade | ||
| Dec 18, 2025 | BTIG | Downgrade | ||
| Jul 15, 2025 | Keybanc | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $50.0M · Total debt $487.0K · Total assets $153.0M · Shareholders' equity $139.0M
- Revenue
- $21.9M
- Operating income
- $4.5M
- Net income
- $3.6M
HistoryDividendAnnual yield
| Institutions | ≈ 78.99% | 15.98M shares | |
|---|---|---|---|
| 171 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 16.93% | 3.42M shares | |
| 7 holders · as of Aug 4, 2026 | |||
| Other | ≈ 4.08% | 825.6K shares | |
| remainder | |||
20.22M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Walter S. WoltoszInsiderdirector, 10 percent owner | 15.83% | 3.20M | filed Jul 6, 2026 |
First Light Asset Management, LLCInstitution | 13.81% | 2.79M | as of Jun 30, 2026 |
Conestoga Capital AdvisorsInstitution | 11.86% | 2.40M | filed Jan 10, 2025 |
BlackRock, Inc.Institution | 7.43% | 1.50M | as of Jun 30, 2026 |
First Eagle Investment Management, LLCInstitution | 5.29% | 1.07M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | John Anthony II DiBella | officer: Chief Revenue Officer | −1,000 | $18.28 |
| Jul 6, 2026 | John Anthony II DiBella | officer: Chief Revenue Officer | −1,000 | $18.36 |
| Jul 1, 2026 | Walter S. Woltosz | director, 10 percent owner: | −4,177 | $18.44 |
| Jun 16, 2026 | Jill Fiedler-Kelly | officer: President, Services Solutions | −7,350 | $18.20 |
| Jun 15, 2026 | Jill Fiedler-Kelly | officer: President, Services Solutions | −1,050 | $16.51 |
- Certara
Closest public MIDD software and biosimulation-services peer
- Schrödinger
Physics-based molecular design software for early drug discovery
- IQVIA
Scale CRO and healthcare-intelligence peer for clinical workflows
- ICON
Global CRO peer for clinical development and pharmacology services
- Thermo Fisher Scientific
PPD-driven CRO and medical-communications overlap
- Revvity
Cheminformatics and scientific-informatics peer in discovery workflows
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Simulations Plus | $18.41 | 0.00% | $372.7M | 46.1 | 21.7 | 4.5 | +7.5% |
| Certara | $8.77 | −0.79% | $1.33B | — | 22.8 | 3.2 | −10.8% |
| Schrödinger | $30.73 | +0.10% | $2.26B | — | — | 8.7 | +7.5% |
| IQVIA | $270.09 | +0.01% | $44.42B | 33.5 | 19.9 | 2.6 | +8.7% |
| ICON | $98.33 | −41.20% | $12.98B | 39.8 | 15.0 | 1.6 | +2.3% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Revvity | $143.31 | 0.00% | $16.02B | 68.4 | 25.5 | 5.5 | −1.3% |
| Median | 37.6 | 22.8 | 4.3 | +4.9% |